Abstract
The antibody monitoring system (AMS) is a crossmatch test using enzyme-linked immunoassay to detect donor-specific anti-HLA antibodies (DSA). The aim of this study was to determine whether the AMS assay is useful for supporting DSA results measured with single-antigen Luminex assay (Luminex-DSA) in renal transplant recipients. Thirty sera from 12 sensitized recipients and 71 sera from 60 non-sensitized recipients were screened by complement-dependent cytotoxic crossmatch (CDC-XM), flow cytometric crossmatch (FCXM), AMS, and the Luminex assays. Twenty-two (73.3%) sera from sensitized patients were positive for Luminex-DSA and the AMS assay revealed the great specificity and positive predictive value for detecting Luminex-DSA in sera from sensitized patients. Positivity in the AMS assay was observed most frequently in Luminex-DSA-positive sera with ≥ 10000 MFI levels (66.7%). Of the 101 sera, the results of the AMS assay were compatible with CDC-XM results in 73 (91.3%) sera and with FCXM results in 72 (90.0%) sera; these rates were significantly higher for the AMS assay than for the Luminex assay (p = 0.008 for CDC-XM and p = 0.001 for FCXM). In conclusion, the AMS assay is useful as a supportive solid-phase method for predicting actual crossmatch and high level of Luminex-DSA in sensitized patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
